name: Breast Cancer by AJCC v8 Prognostic Stage

description: A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)


Stage IIIB Breast Carcinoma

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N0: No regional lymph node metastasis.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


name: Locally Advanced HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Prognostic Stage IIB Breast Cancer AJCC v8

description: Stage IIB includes: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Invasive Male Breast Carcinoma

description: A rare invasive carcinoma that arises from the male breast. Morphologically, it is similar to the invasive carcinomas that arise from the female breast. It usually develops in the retroareolar region.


Anatomic Stage II Breast Cancer AJCC v8

description: Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Low Grade Breast Adenosquamous Carcinoma

description: A low grade metaplastic carcinoma of the breast with morphologic features similar to the adenosquamous carcinoma of the skin.  In the majority of cases the prognosis is excellent.


name: Refractory Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that is resistant to treatment.


name: Noninfiltrating intraductal papillary adenocarcinoma (morphologic abnormality)

description: Breast ductal carcinoma in situ characterized by the presence of filiform arborizing fibrovascular cores lined by neoplastic ductal epithelium. (WHO 2019)


HER2-Low Breast Carcinoma

description: A breast adenocarcinoma defined by low expression of HER2 (IHC1+ or IHC2+; FISH negative).


name: Metastatic Breast Signet Ring Cell Carcinoma

description: A signet ring cell carcinoma that arises from the breast and has metastasized to other anatomic sites.


Breast adenocarcinoma metastatic

description: An adenocarcinoma that arises from the breast and has metastasized to another anatomic site.


name: Recurrent Estrogen Receptor-Positive Breast Carcinoma

description: The reemergence of estrogen receptor-positive breast carcinoma after a period of remission.


Stage II Breast Cancer AJCC v6 and v7

description: Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, M0); (T3, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 2.0 cm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


name: Inflammatory carcinoma of breast recurrent

description: The reemergence of inflammatory carcinoma of the breast after a period of remission


name: Breast Carcinoma with Choriocarcinomatous Features

description: An invasive ductal breast carcinoma, not otherwise specified, characterized by increased levels of human beta-chorionic gonadotropin in the serum.  Morphologic evidence of choriocarcinomatous differentiation is rare.


name: Prognostic Stage II Breast Cancer AJCC v8

description: Stage II includes: IIA: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIB: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Carcinoma in situ of female breast

description: A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the female breast.


name: Intraductal papillary adenocarcinoma with invasion

description: A carcinoma that has papillary growth and invades the wall and/or the surrounding tissues of the organ it originates from.


Recurrent Breast Angiosarcoma

description: The reemergence of breast angiosarcoma after a period of remission.


name: Anatomic Stage IIA Breast Cancer AJCC v8

description: Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Malignant neoplasm of nipple of female breast

description: A malignant neoplasm that affects the area of the nipple in females.


name: Paget's disease and infiltrating duct carcinoma of breast

description: Paget disease involving the skin overlying the mammary gland, accompanied by invasive ductal breast carcinoma.


Anatomic Stage IA Breast Cancer AJCC v8

description: Stage IA includes: T1, N0, M0. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Recurrent Breast Medullary Carcinoma

description: The reemergence of breast medullary carcinoma after a period of remission.


name: Invasive Breast Lobular Carcinoma, Tubulolobular Variant

description: An invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells forming small tubular structures.


name: Hormone Receptor-Negative Breast Carcinoma

description: Breast adenocarcinoma that is negative for hormone receptors.


name: Locally Advanced Estrogen Receptor-Positive Breast Carcinoma

description: Estrogen receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Breast sarcoma recurrent

description: The reemergence of breast sarcoma after a period of remission.


name: Breast Carcinoma with Osseous Metaplasia

description: An invasive breast carcinoma showing differentiation towards bone structures.


Breast Polymorphous Adenocarcinoma

description: A rare, low grade malignant epithelial neoplasm arising from the breast. It is characterized by the presence of uniform, small to medium size malignant epithelial cells and an infiltrating pattern.


Stage III Breast Cancer AJCC v7

description: Stage III includes: IIIA : (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0), IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0), and IIIC: (any T, N3, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


BRCA-Associated Breast Carcinoma

description: Breast carcinoma caused by deleterious germline mutation in a gene of the BRCA family.


name: Unresectable Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast carcinoma that is not amenable to surgical resection.


name: Invasive Breast Carcinoma of No Special Type with Predominant Intraductal Component

description: An invasive breast carcinoma of no special type characterized by the presence of a predominant ductal carcinoma in situ component and a minor component of invasive carcinoma.


name: Prognostic Stage IA Breast Cancer AJCC v8

description: Stage IA includes: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Pleomorphic lobular carcinoma in situ of breast

description: Breast lobular carcinoma in situ characterized by the presence of neoplastic large cells with marked nuclear pleomorphism.


name: Invasive micropapillary carcinoma of breast

description: An invasive breast carcinoma characterized by the presence of clusters of malignant cells located within artifactual clear stromal spaces that resemble vascular spaces.


name: Anatomic Stage IIIB Breast Cancer AJCC v8

description: Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Unilateral Breast Carcinoma

description: Breast carcinoma of one breast, or one side of the breast.


Childhood Malignant Breast Neoplasm

description: A malignant neoplasm that affects the breast and occurs during childhood.


Carcinoma in situ of male breast

description: A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the male breast. It includes the entire spectrum of carcinoma in situ observed in the female breast. It usually develops in the retroareolar region.


name: Paget's disease and intraductal carcinoma of breast

description: Paget disease of the breast associated with the presence of a usually high grade ductal carcinoma in situ in the lactiferous glands.


Stage III Breast Cancer AJCC v6

description: Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.)


Metastatic Breast Lobular Carcinoma

description: A lobular breast carcinoma that has spread from the original site of growth to another anatomic site.


Refractory Breast Adenocarcinoma

description: Breast adenocarcinoma that does not respond to treatment.


name: Invasive Breast Carcinoma by Histologic Grade


Unresectable Breast Carcinoma

description: Breast carcinoma that is not amenable to surgical resection.


name: Recurrent HER2-Negative Breast Carcinoma

description: The reemergence of HER2-negative breast adenocarcinoma after a period of remission.


Breast adenocarcinoma recurrent

description: The reemergence of breast adenocarcinoma after a period of remission.


name: Locally Advanced HER2-Low Breast Carcinoma

description: A HER2-low breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


PALB2-Associated Breast Carcinoma

description: Breast carcinoma caused by deleterious germline mutation in the PALB2 gene.


name: Recurrent Invasive Breast Carcinoma of No Special Type

description: The reemergence of invasive breast carcinoma of no special type after a period of remission.


Metastatic Breast Carcinoma

description: A carcinoma that arises from the breast and has metastasized to another anatomic site.


Refractory Breast Lymphoma

description: Breast lymphoma that is resistant to treatment.


name: Breast Ductal Carcinoma In Situ, Comedo Type

description: Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells with evidence of central necrosis and associated karyorrhectic/nuclear debris.


Occult Breast Carcinoma

description: Breast carcinoma presenting with isolated axillary lymphadenopathy, without clinical or mammographic evidence of breast tumor.


name: Prognostic Stage III Breast Cancer AJCC v8

description: Stage III includes: IIIA: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIIB: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); IIIC: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: solid type ductal carcinoma in situ of breast

description: Breast ductal carcinoma in situ in which the tumor cells fill the ductal spaces as solid sheets.


Malignant nipple neoplasm

description: A malignant neoplasm that affects the area of the nipple.


Recurrent Breast Papillary Carcinoma

description: The reemergence of breast papillary carcinoma after a period of remission.


breast liposarcoma

description: A malignant adipose tissue neoplasm of the breast.


name: Prognostic Stage IV Breast Cancer AJCC v8

description: Stage IV includes: Any T, Any N, M1, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


name: Metastatic Androgen Receptor-Positive Breast Carcinoma

description: Androgen receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


breast sarcoma

description: A malignant mesenchymal neoplasm that arises from the breast. Representative examples include angiosarcoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, and extraskeletal osteosarcoma.


Breast Carcinoma Metastatic in the Lung

description: A carcinoma that arises from the breast and has metastasized to the lung.


Invasive Breast Apocrine Carcinoma

description: An invasive breast adenocarcinoma with cytological and immunophenotypic characteristics of apocrine differentiation in more than 90 percent of the malignant cells.


name: Anatomic Stage IIIC Breast Cancer AJCC v8

description: Stage IIIC includes: Any T, N3, M0. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Metastatic Triple-Negative Breast Inflammatory Carcinoma

description: Triple-negative breast inflammatory carcinoma that has spread from its original site of growth to another anatomic site.


Carcinoma breast stage I

description: Stage 1 includes T1, NO, MO.  T1: Tumor 2.0 cm or less in greatest dimension.  T1mic: Microinvasion 0.1 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th Ed.)-2003


name: Breast Tall Cell Carcinoma with Reversed Polarity

description: A rare subtype of invasive breast carcinoma characterized by tall columnar cells with reversed nuclear polarity, arranged in solid and solid papillary patterns, most commonly associated with IDH2 p.Arg172 hotspot mutations. (WHO 2019)


name: Androgen Receptor-Positive Breast Carcinoma

description: Breast carcinoma that is positive for androgen receptors.


name: Synchronous Ipsilateral Breast Carcinoma

description: Diagnosis of more than one distinct tumor focus in the same breast, within two months.


name: Resectable Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that is amenable to surgical resection.


name: Prognostic Stage IIIC Breast Cancer AJCC v8

description: Stage IIIC includes: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Anatomic Stage IIB Breast Cancer AJCC v8

description: Stage IIB includes: (T2, N1, M0); (T3, N0, M0). T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Grade 1 Invasive Breast Carcinoma

description: A well differentiated invasive breast carcinoma.


name: Unresectable HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that is not amenable to surgical resection.


Secondary malignant neoplasm of breast

description: The spread of a malignant neoplasm to the breast. This may be from a primary breast malignant neoplasm on the opposite side, or from a malignant neoplasm at a distant site.


Grade 3 Invasive Breast Carcinoma

description: A poorly differentiated invasive breast carcinoma.


name: Unresectable Estrogen Receptor-Positive Breast Carcinoma

description: Estrogen receptor-positive breast carcinoma that is not amenable to surgical resection.


Stage IB Breast Cancer AJCC v7

description: Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


breast rhabdomyosarcoma

description: A malignant mesenchymal tumor with skeletal muscle differentiation affecting the breast.


Breast Cancer by AJCC v7 Stage

description: A term that refers to the staging of breast cancer according to the American Joint Committee on Cancer, 7th edition.


Stage IIB Breast Carcinoma

description: Stage IIB includes: (T2, N1, M0); (T3, N0, M0).  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Anatomic Stage IB Breast Cancer AJCC v8

description: Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Breast Ductal Carcinoma In Situ and Lobular Carcinoma

description: A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an in situ or invasive lobular carcinomatous component.


breast extraskeletal osteosarcoma

description: An osteosarcoma arising from the breast tissue.


name: Recurrent Breast Ductal Carcinoma In Situ

description: The reemergence of breast ductal carcinoma in situ after a period of remission.


name: Breast Ductal Carcinoma In Situ, Non-Comedo Type

description: Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells without evidence of central necrosis or cell death.


name: Locally Advanced Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Invasive Breast Lobular Carcinoma, Signet Ring Variant

description: An invasive lobular carcinoma characterized by the presence of malignant epithelial cells with large intracytoplasmic lumina that cause displacement of the nuclei towards one pole of the cells.


name: Prognostic Stage I Breast Cancer AJCC v8

description: Stage I includes: IA: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any); IB: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Anatomic Stage IIIA Breast Cancer AJCC v8

description: Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Metastatic Breast Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the breast parenchyma and has metastasized to other anatomic sites.


Invasive papillary breast carcinoma

description: An invasive breast carcinoma characterized by the presence of papillary structures.


name: adenocarcinoma of breast with spindle cell metaplasia

description: An invasive adenocarcinoma of the breast usually affecting post-menopausal women, characterized by extensive spindle cell metaplasia of the neoplastic glandular cells.


name: Recurrent Progesterone Receptor-Positive Breast Carcinoma

description: The reemergence of progesterone receptor-positive breast carcinoma after a period of remission.


Metastatic Breast Carcinoma in the Skin

description: A carcinoma that arises from the breast and has metastasized to the skin.


Unresectable HER2-Low Breast Carcinoma

description: A HER2-low breast adenocarcinoma that is not amenable to surgical resection.


name: Ductal Carcinoma In Situ with Microinvasion

description: Invasive breast carcinoma measuring 1 mm or less in size.


Early Stage Breast Carcinoma

description: Breast carcinoma that has not spread beyond the breast and the axillary lymph nodes.


Anatomic Stage IV Breast Cancer AJCC v8

description: Stage IV includes: Any T, Any N, M1. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


Unresectable Breast Adenocarcinoma

description: A breast adenocarcinoma that is not amenable to surgical resection.


name: Unresectable Breast Inflammatory Carcinoma

description: Inflammatory breast carcinoma that is not amenable to surgical resection.


Invasive Female Breast Carcinoma

description: An invasive carcinoma that arises from the breast in females.


name: Refractory HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that is resistant to treatment.


name: Breast Carcinoma with Chondroid Metaplasia

description: An invasive carcinoma of the breast showing differentiation towards cartilaginous structures.


Metastatic HER2-Low Breast Carcinoma

description: A HER2-low breast adenocarcinoma that has spread from its original site of growth to another anatomic site.


Hereditary Male Breast Carcinoma

description: Breast carcinoma that has developed in male relatives of patients with history of breast carcinoma.


Recurrent Breast Paget Disease

description: The reemergence of Paget disease of the breast after a period of remission.


name: Early Stage Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that has not spread beyond the breast or axillary lymph nodes.


Locally Advanced Breast Adenocarcinoma

description: Breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Childhood Breast Carcinoma

description: A rare breast carcinoma that occurs during childhood.


name: Breast Ductal Carcinoma with Squamous Metaplasia

description: An invasive breast carcinoma characterized by the presence of a predominant squamous cell component that is admixed with the ductal carcinomatous component.


name: Metastatic Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Stage IA Breast Cancer AJCC v7

description: Stage IA includes: T1, N0, M0.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


breast lymphoma

description: A lymphoma that arises from the breast. There is no history of extramammary breast lymphoma and ipsilateral axillary lymph node involvement does not exclude the diagnosis of primary breast lymphoma. Most patients present with a painless breast lump. The vast majority of cases are B-cell non-Hodgkin lymphomas. Diffuse large B-cell lymphoma, follicular lymphoma, and extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue are the most common types of primary non-Hodgkin lymphoma of the breast. Primary Hodgkin lymphoma of the breast is rare.


name: Invasive Breast Lobular Carcinoma, Pleomorphic Variant

description: A grade II invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells with large and atypical nuclei.


Breast Cancer by AJCC v8 Anatomic Stage

description: A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)


Breast cancer recurrent

description: The reemergence of carcinoma in the breast after a period of remission.


Breast Mixed Carcinoma

description: An invasive breast carcinoma characterized by the presence of more than one malignant epithelial histologic pattern.


name: Breast Carcinoma with Melanotic Features

description: A very rare primary malignant tumor of the breast, characterized by an invasive breast carcinoma that co-exists with a melanoma component.  The vast majority of melanotic tumors that affect the breast are metastatic melanomas that originate in extra-mammary sites.


name: Breast Paget Disease without Invasive Carcinoma

description: Paget disease involving the skin overlying the mammary gland, without accompanying invasive ductal or lobular breast carcinoma.


Refractory Breast Carcinoma

description: Breast carcinoma that does not respond to treatment.


Breast Cancer by AJCC v8 Stage

description: A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)


name: Breast Classic Lobular Carcinoma In Situ Type A

description: Breast classic lobular carcinoma in situ characterized by the presence of neoplastic cells with uniform nuclei.


name: Unresectable Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that is not amenable to surgical resection.


Advanced Breast Carcinoma

description: Breast carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Inflammatory carcinoma of breast stage IV

description: An inflammatory carcinoma of the breast that has spread to other anatomic sites.


name: Metastatic HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that has spread from the original site of growth to another anatomic site.


name: Prognostic Stage IIIB Breast Cancer AJCC v8

description: Stage IIIB includes: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Breast Cancer by AJCC v6 Stage

description: A term that refers to the staging of breast cancer according to the American Joint Committee on Cancer, 6th edition.


Recurrent Breast Lymphoma

description: The reemergence of breast lymphoma after a period of remission.


name: Breast Ductal Carcinoma In Situ, Low Grade

description: Breast ductal carcinoma in situ characterized by the presence of small, monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. The nuclei are uniform and mitotic figures are rare.


Locally Advanced Breast Carcinoma

description: A breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Contralateral Breast Carcinoma

description: Breast carcinoma that develops in the opposite breast of a patient with an already diagnosed primary breast carcinoma.


name: Prognostic Stage IB Breast Cancer AJCC v8

description: Stage IB includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Metastatic Squamous Cell Carcinoma in the Breast

description: A squamous cell carcinoma that has spread to the breast from another anatomic site.


malignant breast melanoma

description: A melanoma that arises usually from the breast skin and less often from the breast glandular tissue. Primary breast melanomas are rare.


name: Prognostic Stage IIA Breast Cancer AJCC v8

description: Stage IIA includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Oligometastatic Breast Carcinoma

description: Breast carcinoma that has metastasized to a limited number of sites.


Encapsulated Breast Papillary Carcinoma

description: Breast carcinoma characterized by the presence of fine fibrovascular stalks covered by neoplastic epithelial cells of low or intermediate nuclear grade, typically present within a cystic space and surrounded by a fibrous capsule. There are usually no myoepithelial cells along the papillae or at the periphery of the lesion. (WHO 2019)


name: Breast Carcinoma Metastatic in the Brain

description: A carcinoma that has spread to the brain from its original site in the breast, through the hematogenous route.


name: Encapsulated Breast Papillary Carcinoma with Invasion

description: Encapsulated breast papillary carcinoma characterized by the presence of neoplastic elements that permeate beyond the fibrous capsule with an irregular infiltrative appearance. (WHO 2019)


name: Breast Carcinoma with Osteoclast-Like Stromal Giant Cells

description: An invasive breast adenocarcinoma characterised by the presence of non-neoplastic stromal osteoclastic giant cells.  The carcinomatous component is usually an invasive ductal carcinoma, although all other breast adenocarcinoma subtypes have also been described.  The prognosis depends on the characteristics of the adenocarcinomatous component, and is not related to the presence of the giant cells.


Grade 2 Invasive Breast Carcinoma

description: A moderately differentiated invasive breast carcinoma.


name: Anatomic Stage III Breast Cancer AJCC v8

description: Stage III includes: IIIA: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IIIC: (Any T, N3, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage I Breast Cancer AJCC v8

description: Stage I includes: IA: (T1, N0, M0); IB: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Malignant Breast Neoplasm

description: A malignant breast neoplasm that has metastasized to another anatomic site.


Resectable Breast Carcinoma

description: Breast carcinoma that is amenable to surgical resection.


name: Low Grade Breast Mucoepidermoid Carcinoma

description: A slow growing mucoepidermoid carcinoma that arises from the breast. It is characterized by the presence of keratinization in the neoplastic squamous cells and lumina formation by glandular neoplastic cells. Complete excision may be curative.


name: Metastatic BRCA-Associated Breast Carcinoma

description: BRCA-associated breast carcinoma that has spread to another anatomic site.


Recurrent Lobular Breast Carcinoma

description: The reemergence of lobular breast carcinoma after a period of remission.


name: Estrogen Receptor-Positive Breast Carcinoma

description: Breast adenocarcinoma that is positive for estrogen receptors.


name: Invasive Breast Lobular Carcinoma with Extracellular Mucin

description: A rare variant of invasive breast lobular carcinoma characterized by the presence of pools of extracellular mucin in which groups of floating lobular carcinoma cells are identified.


name: Breast Ductal Carcinoma In Situ, Intermediate Grade

description: Breast ductal carcinoma in situ characterized by the presence of monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. Intraluminal necrosis is present in some ducts. Ducts that contain neoplastic cells with occasional nucleoli and coarse chromatin may also be present.


name: Recurrent Hormone Receptor-Positive Breast Carcinoma

description: The reemergence of hormone receptor-positive breast adenocarcinoma after a period of remission.


name: adenocarcinoma of breast with squamous metaplasia

description: An invasive breast carcinoma characterized by the presence of a predominant squamous cell component that is admixed with the adenocarcinoma component.


name: Recurrent Triple-Negative Breast Carcinoma

description: The reemergence of triple-negative breast carcinoma after a period of remission.


name: Metastatic Progesterone Receptor-Positive Breast Carcinoma

description: Progesterone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Breast Neuroendocrine Carcinoma

description: A neuroendocrine carcinoma arising from the breast. It is classified as small cell or large cell neuroendocrine carcinoma.


name: Locally Advanced HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Metastatic Hormone Receptor-Negative Breast Carcinoma

description: Hormone receptor-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


Metastatic Breast Ductal Carcinoma

description: A ductal breast carcinoma that has spread from the original site of growth to another anatomic site.


name: Breast Carcinoma Metastatic in the Central Nervous System

description: A carcinoma that has spread to the central nervous system from its original site in the breast, through the hematogenous route.


Recurrent Breast Tubular Carcinoma

description: The reemergence of breast tubular carcinoma after a period of remission.


Stage IIIA Breast Carcinoma

description: Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


small cell carcinoma of breast

description: A poorly differentiated neuroendocrine carcinoma that arises from the breast.  It is characterized by the presence of small neuroendocrine cells and high mitotic activity.


name: Locally Advanced Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


arenesulfonic acid

Organic derivatives of sulfonic acid in which the sulfo group is linked directly to carbon of an aryl group.


aminonaphthalenesulfonic acid

A naphthalenesulfonic acid having at least one amino substituent.


Acute prostatitis

description: An acute inflammatory process that affects the prostate gland.  It is caused by bacteria, most often Escherichia coli, Proteus mirabilis, Klebsiella, and Pseudomonas aeruginosa.


Hernández-Aguirre Negrete syndrome

description: A syndrome is characterized by major seizures, dysmorphic features (round face, bulbous nose, wide mouth, prominent philtrum), pes planus, psychomotor retardation and obesity. It has been described in five children (three boys and two girls, one of whom died in infancy) from two unrelated Mexican families. This condition is likely to be transmitted as an autosomal recessive trait.


Pathology Result

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: The outcome of a pathologic examination.


Osseous metaplasia

description: Heterotopic formation of normal bone within soft tissue.


Large Cell Dysplasia

description: A premalignant neoplastic lesion of the liver.  It is characterized by the presence of hepatocytes with enlarged nuclei and cytoplasm, nuclear pleomorphism, multinucleation, and hyperchromasia.


Intestinal metaplasia of gastric mucosa

description: A morphologic finding indicating the replacement of part of the gastric mucosal epithelium with intestinal-type epithelium.  Using immunohistochemical staining, gastric intestinal metaplasia is classified as complete or incomplete.  Complete intestinal metaplasia is defined by the decreased expression of gastric mucins and expression of the intestinal mucin MUC2.  Incomplete intestinal metaplasia is defined by the co-expression of both gastric mucins and MUC2.


name: progressive transformation of germinal centers

description: Progressive transformation of germinal centers is a condition in which a lymph node becomes very enlarged (lymphadenopathy). Typically, only one lymph node is affected, though PTGC can involve multiple lymph nodes. Theneck is the most common location of affected lymph nodes, but PTGC may also affect lymph nodes in the groin and armpits. adults are more frequently affected than children, but children have a higher chance of developing PTGC multiple times (recurrence). PTGC is not considered a precancerous condition, though it has been associated with Hodgkin lymphoma.


Epithelial metaplasia

description: A morphologic finding that refers to the replacement of a group of one type of epithelial cells (e.g., glandular epithelial cells) to another type of epithelial cells (e.g., squamous epithelial cells).


Endometrial metaplasia

description: A morphologic finding indicating the alteration of the mature endometrial glandular epithelium to another that differs from that of normal endometrioid glands.


Deposit

description: Accumulation of extraneous inorganic matter in tissues or cavities.


cervical metaplasia

description: Metaplastic changes in the cervical glandular or squamous epithelium.


Histopathology Result

description: A finding resulting from the examination of a tissue sample under light or electron microscopy.


angiomatosis

description: A benign diffuse vascular proliferation usually occurring in young adults. It is characterized by the formation of capillary-sized and cavernous vascular spaces. Patients present with diffuse persistent swelling.


name: Intestinal Metaplasia of Columnar Epithelium

description: A morphologic finding indicating the replacement of part of the columnar epithelium by intestinal-type epithelium.


Transitional cell metaplasia

description: A morphologic finding that refers to the replacement of non-transitional epithelium (e.g., squamous epithelium) with transitional epithelium.


nephrogenic adenoma

description: So-called nephrogenic adenoma is a distinct metaplastic lesion of the urothelium characterized by aggregates of cuboidal or hobnail cells. These cells line thin papillary fronds on the surface or form tubular structures within the lamina propria.


Squamous Metaplasia Without Atypia

description: A morphologic finding indicating the transformation of glandular or transitional epithelial cells to squamous epithelial cells that lack atypical features.


name: Cartilaginous Metaplasia of Malignant Cells Present


Central Nervous System Necrotic Lesion

description: A necrotic process affecting the brain and/or spinal cord.


Focal Cortical Dysplasia Type 2

description: Focal cortical dysplasia characterized by disrupted cortical lamination and specific cytological abnormalities. It includes type IIa with dysmorphic neurons and type IIb with dysmorphic neurons and balloon cells.


Tuboendometrioid Metaplasia

description: Replacement of the endocervical-type epithelium of the cervix by benign tubal or endometrioid epithelium.


Smooth Muscle Metaplasia

description: A morphologic finding indicating the transformation of non-smooth muscle cells to smooth muscle cells.


Reticulin Fibrosis of the Bone Marrow

description: Increased reticular fiber deposition within bone marrow.


name: Mesenchymal Metaplasia of Malignant Cells Present


Fallopian Tube Mucinous Metaplasia

description: Metaplastic mucinous changes in the fallopian tube epithelium. It may be seen in association with gynecological, appendiceal, or colonic mucinous tumors, or chronic inflammation.


Small Cell Dysplasia

description: A premalignant neoplastic lesion of the liver.  It is characterized by the presence of hepatocytes with decreased cell volume, increased nuclear/cytoplasmic ratio, basophilia, mild nuclear pleomorphism, and hyperchromasia.


Focal Cortical Dysplasia

description: A congenital cortical developmental abnormality characterized by focal architectural distortion of the cortical brain layers. It is associated with the presence of cytologic abnormalities including hypertrophic and dysmorphic neurons. It is caused by genetic or acquired factors and is often associated with epilepsy.


Apocrine metaplasia

description: A morphologic finding indicating the alteration of the glandular acinar epithelial cells to apocrine sweat gland cells.


name: Squamous Metaplasia of Malignant Cells Present


name: Massive Sinusoidal Histiocytic Infiltrate


Focal fibrosis

description: Localized formation of fibrous tissue.


advanced hepatic fibrosis

description: Septal or bridging fibrosis that results in the disruption of normal blood flow and liver function, and extends across hepatic lobules with significant porto-portal or porto-central bridging. Progression may lead to the formation of nodules that distort the liver architecture, which is termed cirrhosis.


name: Spindle Cell Metaplasia of Malignant Cells Present


Cervical Transitional Metaplasia

description: Cervical metaplasia in which the cervical squamous epithelium resembles benign urothelium as a result of a lack of cellular maturation.


Vaginal Transitional Cell Metaplasia

description: Vaginal metaplasia in which the vaginal surface squamous epithelium resembles benign transitional urothelium.


name: Concentric Fibrosis of Intrahepatic Duct

description: A morphologic finding indicating the presence of fibrosis around an intrahepatic bile duct in the liver tissue.


Focal Cortical Dysplasia Type 3

description: Focal cortical dysplasia characterized by different cortical dyslamination and cytological abnormalities with the main lesions located in the same area. It includes the following: type IIIa with architectural distortion of cortical layer in temporal lobe with hippocampal atrophy; type IIIb with architectural distortion of cortical layer adjacent to glial or glioneuronal tumor; type IIIc with architectural distortion of cortical layer adjacent to vascular malformation; and type IIId with architectural distortion of cortical layer adjacent to other lesions acquired in early childhood (e.g., trauma, ischemic event, and encephalitis).


Morular Metaplasia of the Endometrium

description: A morphologic finding indicating the replacement of part of the glandular endometrial epithelium by nodular structures that contain non-keratinizing squamous cells.


Morphologic Finding

description: A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.


Kidney Fibrosis

description: Excessive intraglomerular or interstitial accumulation of extracellular matrix proteins in the kidney, leading to the destruction of adjacent cellular structures and nephron loss.


Squamous Metaplasia of Bronchial Mucosa

description: Replacement of the bronchial glandular epithelial cells by squamous cells.


Columnar Metaplasia

description: A morphologic finding indicating the transformation of non-columnar epithelial cells into columnar cells.


Dystrophic Calcification

description: Calcium deposits in  degenerated or necrotic tissue without abnormalities in blood calcium.


name: Hurthle cell metaplasia of thyroid gland

description: A morphologic finding indicating transformation of follicular cells to large cells with abundant eosinophilic and granular cytoplasm (Hurthle cells) in the thyroid gland.


Apocrine metaplasia of breast

description: A morphologic finding indicating the transformation of the epithelial cells in a breast tissue sample to cells with abundant eosinophilic cytoplasm.


Glandular metaplasia

description: A morphologic finding indicating the alteration of the squamous or transitional epithelial cells to glandular cells.


name: Microcalcification Present in Neoplastic and Non-Neoplastic Tissue

description: A finding of microcalcifications located within neoplastic tissue, and in tissues without neoplasm.


Mesenchymal Metaplasia

description: A morphologic finding that refers to the transformation or replacement of a group of non-mesenchymal cells into osseous, cartilagenous, or lipomatous cells.


name: Microcalcification Present in Neoplastic Tissue

description: A finding of microcalcifications located within neoplastic tissue.


name: Intestinal Metaplasia of Esophageal Mucosa

description: A finding indicating the replacement of part of the esophageal mucosal epithelium by intestinal-type epithelium.


Bridging fibrosis

description: A morphologic finding indicating the presence of fibrous bands connecting portal tracts, portal tracts and centrilobular spaces, or centrilobular spaces in a liver tissue sample in a patient with evolving cirrhosis.


Muscle Cell Hypertrophy

description: A morphologic finding indicating the presence of enlarged muscle cells in a muscle tissue sample.


Squamous metaplasia

description: A morphologic finding indicating the transformation of glandular or transitional epithelial cells to, usually, mature squamous epithelial cells.  Representative examples include squamous metaplasia of bronchial epithelium, cervix, urinary bladder, and prostate gland.


Dysplasia

description: A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns. The cellular changes include nuclear and cytoplasmic abnormalities. Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer.


Peritoneal Transitional Cell Metaplasia

description: A morphologic finding that refers to the replacement of peritoneal mesothelium with transitional epithelium.


Intestinal metaplasia

description: A morphologic finding indicating the replacement of epithelial tissue outside the intestines by intestinal-type epithelium.


Glomerular Hypertrophy

description: A morphologic finding indicating enlargement of the glomeruli in a kidney specimen.


Fibrosis deep connective tissue

description: Fibrotic degeneration of the deep connective tissues.


name: Microcalcification Present in Non-Neoplastic Tissue

description: A finding of microcalcifications located within tissues without neoplasm.


Extraskeletal calcification

description: Deposition of calcium in tissues outside of bone.


Spindle Cell Metaplasia

description: A morphologic finding indicating the transformation of non-spindle cells to spindle-shaped cells.


Breast Microcalcification

description: Tiny deposits of calcium in tissue.  In the breast they can be seen using mammography, and if found in clusters may be indicative of breast cancer.


Focal Cortical Dysplasia Type 1

description: Focal cortical dysplasia characterized by abnormal cortical layering. It is associated with mild symptoms, late onset, and changes present in the temporal lobe. It includes the following: type Ia with abnormal radial migration and maturation of neurons; type Ib with disruption of the six-layered tangential composition of the cortex with immature neurons; and type Ic comprising both architectural abnormalities.


Squamous metaplasia of cervix

description: The process in which the cervical glandular epithelium is replaced with squamous epithelium.


name: Minimal Reticulin Fibrosis of the Bone Marrow


Superficial Soft Tissue Fibrosis

description: Fibrotic degeneration of the superficial soft tissues.


Metaplasia of Malignant Cells Present

description: Transformation of malignant cells with a specific differentiation to different morphologic types.


name: Osseous Metaplasia of Malignant Cells Present


Fatty degeneration

description: Acumulation of adipose tissue in intracytoplasmic or extracellular spaces.


name: Refractory Malignant Gastrointestinal Stromal Tumor

description: Malignant gastrointestinal stromal tumor that is resistant to treatment.


Refractory Soft Tissue Sarcoma

description: A soft tissue sarcoma that does not respond to treatment.


Refractory Epithelioid Sarcoma

description: An epithelioid sarcoma that does not respond to treatment.


Refractory Synovial Sarcoma

description: Synovial sarcoma that does not respond to treatment.


name: Refractory Extraskeletal Myxoid Chondrosarcoma

description: Extraskeletal myxoid chondrosarcoma that does not respond to treatment.


name: Refractory Undifferentiated Pleomorphic Sarcoma

description: Undifferentiated pleomorphic sarcoma that does not respond to treatment.


Refractory Alveolar Rhabdomyosarcoma

description: Alveolar rhabdomyosarcoma that does not respond to treatment.


Refractory Kaposi Sarcoma

description: Kaposi sarcoma that is resistant to treatment.


Refractory Alveolar Soft Part Sarcoma

description: Alveolar soft part sarcoma that is resistant to treatment.


name: Refractory Childhood Soft Tissue Sarcoma

description: Childhood soft tissue sarcoma that is resistant to treatment.


name: Refractory Desmoplastic Small Round Cell Tumor

description: Desmoplastic small round cell tumor that is resistant to treatment.


Refractory Childhood Rhabdomyosarcoma

description: Childhood rhabdomyosarcoma that is resistant to treatment.


Refractory Rhabdomyosarcoma

description: Rhabdomyosarcoma that does not respond to treatment.


orbit embryonal rhabdomyosarcoma

description: A malignant mesenchymal neoplasm that arises from the orbit. It is characterized by the presence of skeletal muscle tissue exhibiting embryonic features.


Metastatic embryonal rhabdomyosarcoma

description: Embryonal rhabdomyosarcoma that has spread from its original site of growth to another anatomic site.


Middle Ear Embryonal Rhabdomyosarcoma

description: A rare embryonal rhabdomyosarcoma that arises in the middle ear.


name: adult vagina botryoid embryonal rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma arising from the vagina. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules with an abundant myxoid stroma. It occurs in female adults.


botryoid rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma arising from organs with a mucosal epithelial surface. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules within an abundant myxoid stroma.


adult botryoid rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma occurring in adults. The neoplasm arises from organs containing a mucosal epithelial surface. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules with an abundant myxoid stroma.


name: childhood vagina botryoid rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma occurring in female children. The neoplasm arises from the vagina. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules with an abundant myxoid stroma.


embryonal rhabdomyosarcoma of bladder

description: An embryonal rhabdomyosarcoma arising from the bladder. It is the most common type of rhabdomyosarcoma of the bladder affecting young children.


prostate embryonal rhabdomyosarcoma

description: A malignant mesenchymal neoplasm of the prostate. It is characterized by the presence of skeletal muscle exhibiting embryonic features.


Anaplastic embryonal rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma.  It is characterized by the presence of large hyperchromatic and anaplastic cells.


name: vulvar childhood botryoid-type embryonal rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma occurring in female children. The neoplasm arises from the vulva. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules with an abundant myxoid stroma.


childhood botryoid rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma occurring in children. The tumor arises from organs with a mucosal epithelial surface. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules within an abundant myxoid stroma.


name: botryoid-type embryonal rhabdomyosarcoma of the vagina

description: A morphologic variant of embryonal rhabdomyosarcoma arising from the vagina. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules within an abundant myxoid stroma.


Childhood Embryonal Rhabdomyosarcoma

description: A poorly circumscribed morphologic variant of rhabdomyosarcoma occurring in children.  The neoplasm is characterized by the presence of primitive skeletal muscle in any stage of myogenesis.


name: Stage 0 Lip Basal Cell Carcinoma AJCC v6 and v7


Atypical cartilaginous tumor

description: A locally aggressive, low grade chondrosarcoma arising in the medulla of bone or within the cartilaginous cap of a pre-existing osteochondroma in the appendicular skeleton.


Central Atypical Cartilaginous Tumor

description: A locally aggressive, low-grade chondrosarcoma arising in the medulla of bone in the appendicular skeleton.


name: Secondary Peripheral Atypical Cartilaginous Tumor

description: A locally aggressive, low-grade chondrosarcoma arising within the cartilaginous cap of a pre-existing osteochondroma in the appendicular skeleton.


cortistatins

Any member of a class of steroidal alkaloids obtained from the marine sponge Corticium simplex, with a basic skeleton that is (5R,8beta)-5,8-epoxy-9,19-cyclo-9,10-secoandrostane, bearing a dimethylamino substituent at position 3 and an isoquinolin-7-yl or isoquinolin-7-yl-derived substituent at position 17. They selectively inhibit proliferation of human umbilical vein endothelial cells (HUVECs).


Stage IIIa Penile Cancer AJCC v7

description: Stage IIIa includes: T1-3, N1, M0.  T1: Tumor invades subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (i.e., grade 3-4) or tumor invades subepithelial connective tissue with lymph vascular invasion or is poorly differentiated.  T2: Tumor invades corpus spongiosum or cavernosum.  T3: Tumor invades urethra.  cN1: Palpable mobile unilateral inguinal lymph node.  pN1: Metastasis in a single inguinal lymph node.  M0: No distant metastasis. (AJCC 7th ed.)


Penile Cancer by AJCC v7 Stage

description: A term that refers to the staging of penile carcinoma according to the American Joint Committee on Cancer, 7th edition.


Stage IIIb Penile Cancer AJCC v7

description: Stage IIIb includes: T1-3, N2, M0.  T1: Tumor invades subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (i.e., grade 3-4) or tumor invades subepithelial connective tissue with lymph vascular invasion or is poorly differentiated.  T2: Tumor invades corpus spongiosum or cavernosum.  T3: Tumor invades urethra.  cN2: Palpable mobile multiple or bilateral inguinal lymph nodes. pN2: Metastasis in multiple or bilateral superficial inguinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Penile Cancer AJCC v7

description: Stage IV includes: (T4, Any N, M0); (Any T, N3, M0); (Any T, Any N, M1).  T4: Tumor invades other adjacent structures.  cN3: Palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral.  pN3: Extranodal extension of lymph node metastasis or pelvic lymph node(s) unilateral or bilateral.  M0: No distant metastasis. M1: Distant metastasis (lymph node metastasis outside of the true pelvis in addition to visceral or bone sites).  (AJCC 7th ed.)


Stage II Penile Cancer AJCC v7

description: Stage II includes: (T1b, N0, M0); (T2, N0, M0); (T3, N0, M0).  T1b: Tumor invades subepithelial connective tissue with lymph vascular invasion or is poorly differentiated.  T2: Tumor invades corpus spongiosum or cavernosum.  T3: Tumor invades urethra.  cN0: No palpable or visibly enlarged inguinal lymph nodes.  pN0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage I Penile Cancer AJCC v7

description: Stage I includes: T1a, N0, M0.  T1a: Tumor invades subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (i.e., grade 3-4).  cN0: No palpable or visibly enlarged inguinal lymph nodes.  pN0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage III Penile Cancer AJCC v7

description: Stage III includes: IIIa (T1-3, N1, M0); IIIb (T1-3, N2, M0).  T1: Tumor invades subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (i.e., grade 3-4) or tumor invades subepithelial connective tissue with lymph vascular invasion or is poorly differentiated.  T2: Tumor invades corpus spongiosum or cavernosum.  T3: Tumor invades urethra.  cN1: Palpable mobile unilateral inguinal lymph node.  pN1: Metastasis in a single inguinal lymph node.  cN2: Palpable mobile multiple or bilateral inguinal lymph nodes. pN2: Metastasis in multiple or bilateral superficial inguinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage 0 Penile Cancer AJCC v7

description: Stage 0 includes: (Tis, N0, M0); (Ta, N0, M0).  Tis: Carcinoma in situ.  Ta: Non-invasive verrucous carcinoma.  cN0: No palpable or visibly enlarged inguinal lymph nodes.  pN0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


myelofibrosis

description: A partial or complete replacement of the bone marrow stroma by fibrous tissue. It can be a primary bone marrow lesion as part of the chronic myeloproliferative disorders (chronic idiopathic myelofibrosis), a manifestation of acute myeloid leukemia (acute panmyelosis with myelofibrosis), or a secondary phenomenon due to bone marrow involvement by a metastatic tumor (e.g., metastatic breast carcinoma). --2003


name: macular coloboma-cleft palate-hallux valgus syndrome

description: Macular coloboma-cleft palate-hallux valgus syndrome is characterized by the association of bilateral macular coloboma, cleft palate, and hallux valgus. It has been described in a brother and sister. Pelvic, limb and digital anomalies were also reported. Transmission is autosomal recessive.


yellow fever

description: Yellow fever (YF), caused by YF virus, is a zoonotic disease characterized by fever and constitutional symptoms, with the potential to progress to severe and fatal viral hemorrhagic fever with shock and multi-organ system failure.


Neuroma of amputation stump

description: A neuroma that occurs at the site of an amputation.


Traumatic neuroma

description: A non-neoplastic proliferation of a nerve caused by injury to the nerve due to trauma or surgery. It presents as a firm nodule that may be associated with pain or tenderness. It most often occurs in the lower extremity following amputation, or in the head and neck region.


Morton neuroma

description: Compressive neuropathy of the forefoot interdigital nerve chiefly due to compression and irritation at the plantar aspect of the transverse intermetatarsal ligament. It is not a true neuroma as the condition is degenerative rather than neoplastic. The most common location for Morton neuroma is between the 2nd and 3rd metatarsals.